TY - JOUR T1 - Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy) JF - medRxiv DO - 10.1101/2020.04.20.20068056 SP - 2020.04.20.20068056 AU - Massimo Lazzeri AU - Stefano Duga AU - Elena Azzolini AU - Vittorio Fasulo AU - Nicolò Buffi AU - Alberto Saita AU - The Humanitas COVID-19 Task Force AU - The Humanitas Gavazzeni COVID-19 Task Force AU - Rodolfo Hurle AU - Alessandro Nobili AU - Maurizio Cecconi AU - Paolo Casale AU - Rosanna Asselta Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/21/2020.04.20.20068056.abstract N2 - Importance There are gender differences in vulnerability to the Coronavirus disease 2019 (COVID-19), with men experiencing more severe disease at any age. The use of anti-androgen drugs, like 5-alpha reductase inhibitors (5ARIs), could protect from severe pulmonary disease.Objective To determine whether men who received 5ARIs for benign prostatic hyperplasia (BPH) have a lower risk of hospitalization for COVID-19.Design This is a case-control study on patients hospitalized for COVID-19 (cases), matched to beneficiaries of the Lombardy Regional Health Service (controls).Setting Data were collected by two high-volume COVID-19 regional centres of Lombardy (Italy) from 1st March to 24th April 2020.Participants Consecutive patients positive for SARS-CoV-2 virus according to the WHO guidance, who required hospitalization.Exposure BPH treatment with 5ARIs (finasteride/dutasteride) in the last six months.Main Outcome(s) and Measure(s) The primary outcome was to compare the prevalence of male patients chronically exposed to 5ARIs, who required hospitalization for COVID-19, with the one of age-matched males in Lombardy.Results Overall, 1,432 COVID-19 patients were included. Among the 943 males, 45 (4.77%) patients were exposed to chronic 5ARI therapy. COVID-19 patients aged >55 years under 5ARI treatment were significantly less than expected on the basis of the prevalence of 5ARI treatment among age-matched controls (5.57 vs. 8.14%; p=0.0083, 95%CI=0.75-3.97%). This disproportion was even higher for men aged >65 (7.14 vs. 12.31%; p=0.0001, 95%CI=2.83-6.97%).Eighteen 5ARIs-patients died; the mean age of men who died was higher than those who did not: 75.98±9.29 vs. 64.78±13.57 (p<0.001). Cox regression and multivariable models did not show any correlation between the exposure to 5ARIs and protection against ICU admission or death: HR=0.79 (95%CI=0.54-1.15; p=0.22) and OR=1.23 (95%CI=0.81-1.87; p=0.33), respectively.Conclusions and Relevance In this case-control study the use of 5ARIs was less frequent among patients hospitalized for COVID-19 than among controls, suggesting that men exposed to 5ARIs might be less vulnerable to severe COVID-19. This observation further supports the idea to test in randomized clinical trials whether anti-androgen therapies can prevent the transition from paucisymptomatic SARS-CoV-2 infection to overt pulmonary disease.Question May treatment of benign prostatic hyperplasia with 5-alpha reductase inhibitors (5ARIs) impact on COVID-19-related hospitalization risk?Findings In this case-control study, which compared 943 adult males hospitalized for COVID-19 with age-matched men from Lombardy (all beneficiaries of the Regional Health Service), the proportion of patients aged >55 years, who were exposed to 5ARIs (dutasteride, finasteride), was significantly lower (5.57%) than that of the general male population (8.14%) (p=0.0083, 95%CI=0.75-3.97%).Meaning The use of 5ARIs was associated with a potential reduced risk of hospitalization for COVID-19 in men older than >55 years. This suggests the opportunity to test whether anti-androgen therapies can prevent the transition from paucisymptomatic SARS-CoV-2 infection to overt pulmonary disease.Competing Interest StatementThe authors have declared no competing interest.Funding Statement-Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot applicable ER -